A similar pattern was observed in vivo: Tumour biopsies from nine stage IV melanoma patients, treated with the BRAF inhibitors vemurafenib or dabrafenib, showed increased PS102-YB-1 levels after the development of drug resistance compared to the tumours before the start of treatment (Figure 1C, Supplementary Figure 1). The gene discussed is BRAF; the disease is melanoma.